Navigation Links
Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
Date:3/7/2012

NATICK, Mass., March 7, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces nine presentations covering its Selective Inhibitors of Nuclear Export (SINE), oral small molecule CRM1 antagonists, at the AACR meeting on March 31 – April 4, 2012, in Chicago.  The presentations are being made by academic collaborators studying the use of Karyopharm's novel SINE, along with Karyopharm scientists, for the treatment of prostate, pancreatic, melanoma, colorectal, non-Hodgkin's lymphoma (NHL), and Ph+ acute leukemias.  In addition, in a late breaking abstract, Dr. Cheryl London of Ohio State University will present the use of SINE compounds to treat spontaneous chemotherapy resistant canine lymphomas.

Dr. William Senapedis of Karyopharm will make an oral presentation in Experimental and Molecular Therapeutics Session 25 (Room W185 McCormick Place West Level 1) on Monday, April 2, 2012, between and 3:00 and 5:00 PM, entitled "KPT-SINE (Selective Inhibitors of Nuclear Export) induce apoptosis in colon cancer cells in vitro and in vivo through nuclear localization of Tumor Suppressor Proteins (TSPs)" (Abstract 2943).

In our first reports of activity in spontaneous chemotherapy-resistant tumors in larger animals, Dr. Cheryl London of Ohio State University will present "Preliminary results of a phase I study of the novel CRM1 inhibitors KPT-276 and KPT-335 in dogs with spontaneous cancer" on Tuesday, April 3, 2012 in the Poster Section: Late-Breaking Research: Clinical Trials (8:00 AM - 12:00 PM), Hall F (Abstract LB-232; Section 40).

All other poster presentations will take place on Monday, April 2, 2012, 8:00AM-12:00 noon in Hall F, Experimental and Molecular Therapeutics 12.

Drs. Giovanni Gravina and Claudio Festuccia of University of L'aquila, Italy, will present "Selective inhibitors of nuclear export (SINE) activate multiple tumor suppressor pathway
'/>"/>

SOURCE Karyopharm Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
2. Incline Therapeutics to Present at the Cowen and Company 32nd Annual Health Care Conference
3. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
4. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
5. Orexigen Therapeutics to Present at Upcoming Conferences
6. ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets
7. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
8. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
10. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... N.J. , Nov. 24, 2014  IGI Laboratories, ... based specialty generic pharmaceutical company, today announced ... (ANDA) to the U.S. Food and Drug Administration (FDA), ... in 2014 to seven, with eighteen submissions now pending ... , President and CEO of the Company, commented, "Our ...
(Date:11/24/2014)... Belgium , Nov. 24, 2014 VolitionRx ... developing diagnostic tests for cancer and other conditions, today announced ... presented at the Science for Business BioWin Day 2014, being ... . The data come from VolitionRx,s lung cancer pilot study, ... of the Centre Hospitalier Universitaire (CHU) de Liege in ...
(Date:11/24/2014)... Washington, USA (PRWEB) November 23, 2014 One ... dynamic field of optics and photonics is now available to ... or very low cost. SPIE, the international society for ... access to the complete SPIE Digital Library available ... subsidized price. , “Light-based technologies are integral to all areas ...
(Date:11/24/2014)... Massachusetts (PRWEB) November 24, 2014 ... Panels ” from METTLER TOLEDO demonstrates how to ... , Power analytics and sample panel design can ... cycle chemistry and protect against corrosion and deposition. ... up a significant amount of panel space. Additionally, ...
Breaking Biology Technology:IGI Laboratories, Inc. Announces ANDA Submission 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2New Video Shows How to Simplify Cycle Chemistry Sample Panels to Save Time and Costs 2
... to high quality, practice management and reimbursement content ... available through web-based delivery platform, DALLAS-FORT ... develops products and services to help accelerate,advancements in the ... in web-based delivery of healthcare,information, have joined forces to ...
... Aton Pharma, Inc., a,global specialty pharmaceutical ... an expanded, comprehensive distribution program that ... resources, for the,dry eye medication Lacrisert(R) ... unique preservative-free, once-daily*, sustained,release prescription insert ...
... the active elements in the next generation of electronic ... nanotubes within device architectures. Most of the approaches for ... applicable to discrete devices and are not readily scalable ... nanotube-based chips. Now, this seemingly intractable problem has been ...
Cached Biology Technology:Oncology Metrics and E-Expert Reimbursement Partners Announce Joint Marketing and Product Development Agreement 2Oncology Metrics and E-Expert Reimbursement Partners Announce Joint Marketing and Product Development Agreement 3Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 2Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 3Nanotubes go with the flow 2
(Date:11/6/2014)... metastasis, yet progress in preventing and treating migratory ... particularly challenging to design drugs that work against ... biology at Harvard Medical School. , "Unfortunately, ... metastasized." , Gujral and colleagues have now identified ... understand how metastasis begins. Their findings may also ...
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
(Date:11/5/2014)... career to understanding the Earth,s climate and communicating ... deputy director and regional climatologist for the Western ... Redmond has more than three decades of experience ... data to the general public. , At its ... December 15-19, 2014 the American Geophysical Union (AGU) ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... Duchenne muscular dystrophy (DMD) face a future of rapidly weakening ... failure before their 30th birthday. While researchers are hopeful that ... have targeted the heart of the problem as much as ... grant he received from the National Institutes of Health will ...
... of toxicity in the four hemophilia B patients enrolled to ... development at St. Jude Children,s Research Hospital and UCL (University ... This trial was designed primarily as a safety test, with ... little detectable Factor IX. The Factor IX protein helps the ...
... LLC, the image analysis and pattern recognition technology ... was awarded best performance for forensic signature verification ... Handwriting Recognition (ICFHR2010) in Kolkata, India, held November ... participants representing a total of 10 offline signature ...
Cached Biology News:New NIH grant helps MU scientist get to the heart of muscular dystrophy 2Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B 2Parascript SignatureXpert Wins Forensic Signature Verification Competition 2
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... & SSM4, Small space saving design - ideal ... of two models: , - 3D gyratory action ... , Digital speed control and built-in timer , Optional ... rockers are ideal where gentle mixing is required, either ...
... provides optimized reagents and protocols for the ... by insertion of group II introns. The ... II introns and utilizes a simple PCR ... intron for specific insertion into the host ...
...
Biology Products: